Impact of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients with Helicobacter pylori Infection

Background and objectives: Helicobacter pylori infection is prevalent and persistent in some cases. The rising incidence of drug resistance in this infection necessitates enhanced treatment methodologies. Our aim was to compare the efficacy of conventional therapy with that of a clinical pharmacist-led intervention for the management of Helicobacter pylori infection. Methods: This randomized controlled trial included 100 therapy-naïve patients with confirmed Helicobacter pylori infection, recruited from an outpatient private clinic in Koye-Erbil, Iraq, between May and November 2023. Patients were randomly assigned to either the control group (receiving conventional therapy) or the intervention group (receiving additional clinical pharmacist-led interventions focused on personalized treatment plans, patient education, and adherence support). Treatment success was assessed using the Helicobacter pylori stool antigen test for follow up one-month post-treatment. Medication compliance was evaluated using the Morisky-Green scale. Results: In this study, 54 (54.0) patients were female and 46 (46.0) patients were male. The intervention group showed a significantly higher rate of H. pylori eradication, with 42 (84%) patients testing negative in the second stool antigen test compared with 28 (56%) patients in the control group (p ? 0.002). Furthermore, medication compliance was significantly better in the intervention group of 36 (72%) patients compared to the control group of 18 (29%) patients (p < 0.013). Conclusion: Clinical pharmacist interventions improve therapeutic outcomes and medication compliance in patients with Helicobacter pylori infection. Although integrating into peptic ulcer disease management teams enhances the treatment effectiveness.